MedPal AI (MPAL) H2 2025 earnings summary

Executive summary

• Transitioned from pre-revenue to fully operational, vertically integrated digital health and pharmacy platform within six months of AIM admission.

• Raised £2 million at IPO and an additional £2.54 million post year-end through equity placements and an ATM facility.

• Acquired key pharmacy assets, launched a 24/7 AI-powered distribution centre, and integrated digital health and pharmacy services.

• Achieved over £350,000 monthly pharmacy revenue post year-end, with 70,384 items dispensed in two months.

• Strategic partnerships established with Epassi UK and Independent Gyms, expanding app reach to over 11 million employees.

Financial highlights

• Loss before tax for the year ended 31 August 2025 was £4,001,912, compared to £13,587 in the prior year.

• Administrative expenses totaled £2,158,714, with significant share-based payment charges of £2,385,347.

• Cash resources at year-end were £1,537,124, up from £253 the previous year.

• No revenue was generated during the reporting period; revenue commenced post year-end.

• Total carried forward tax losses of £4,015,499, with no deferred tax asset recognized.

Outlook and guidance

• Positioned for scalable, capital-efficient growth with a national robotic distribution centre and direct AI-to-pharmacy integration.

• Focus remains on scaling operations, expanding user base, and deepening pharmacy capabilities.

• Directors and Board express confidence in future growth and long-term value creation.